Hillstream BioPharma R&D Day Highlights Ferroptosis, the Non-Genetic Novel, Emerging Mechanism of Action, Targeting Drug Resistant and Devastating Cancers
02. März 2022 08:37 ET
|
Hillstream BioPharma Inc.
HSB-1216’s active moiety in clinical pilot study produced a 71% response rate in TNBC and epithelial carcinomasHSB-1216 was recently granted Orphan Drug Designation to treat Uveal Melanoma by the...